| ²é¿´: 1408 | »Ø¸´: 5 | ||
chendong0625Òø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
¼±£¡ËÄܽøÈëPharmaprojectsÊý¾Ý¿â£¿£¿
|
| ÐèÒª²éÒ»¸öÒ©ÎïµÄÏúÊÛ¶î¡£ |
» ²ÂÄãϲ»¶
¡¾2026 ˶ʿµ÷¼Á¡¿ È«¹úÖØµãʵÑéÊÒ Ò©Ñ§ »¯Ñ§ ÉúÎïѧ ÉúÎïÓëÒ½Ò©
ÒѾÓÐ0È˻ظ´
ҩѧ »¯Ñ§ ÉúÎïѧ ÉúÎïÓëÒ½Ò© ºÓÄÏʦ·¶´óѧ¿¹²¡¶¾ÐÔ´«È¾²¡´´ÐÂÒ©ÎïÈ«¹úÖØµãʵÑéÊÒ
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ62È˻ظ´
½Î÷
ÒѾÓÐ13È˻ظ´
Ò½Ò©Ñз¢Êý¾Ý¿â×ÊÔ´
ÒѾÓÐ4È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧ086ÉúÎïÓëÒ½Ò©
ÒѾÓÐ15È˻ظ´
½¥¶³Ö¢²¡Òò¼°¸ÉÔ¤·½°¸È«Ð½âÎö
ÒѾÓÐ2È˻ظ´
ÇóÖúÓÃ΢Æ×Êý¾Ý¿â²éѯÏà¹ØÎÄÏ×ÐÅÏ¢£¬·Ç³£¸Ðл
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ËÄܸøÍƼö¼¸ÖкõĻ¤Î¸µÄÒ©
ÒѾÓÐ8È˻ظ´
¡¾Óн±»î¶¯¡¿Õ÷¼¯Ãâ·ÑÏÂÔØÈ«ÎĵÄÊý¾Ý¿â
ÒѾÓÐ226È˻ظ´
Ôõô²ÅÄÜÖªµÀÒª²éµÄÎÄÕÂÔÚÄĸöÊý¾Ý¿âÊÕ¼
ÒѾÓÐ12È˻ظ´
ÇóÖúChemical Physics LettersµÄ¼¼ÊõÉó²é°¡£¡¼±
ÒѾÓÐ9È˻ظ´
pharmaprojects
ÒѾÓÐ5È˻ظ´
¡¾ÇóÖú¡¿¼±£¡ÇóÖúPyBOPÓë·¼°·µÄ·´Ó¦
ÒѾÓÐ8È˻ظ´
¼±£¡ÇóÖú£¬¿É²»¿ÉÒÔ°ïæ°Ñ¼¸×éÊý¾ÝÓÃOrigin×öµ½Ò»¸öͼÖÐ
ÒѾÓÐ5È˻ظ´
¡¾ÇóÖú/½»Á÷¡¿ËÓùýRNase°¡£¿
ÒѾÓÐ12È˻ظ´
ÓÐËÖªµÀ²£Á§±êÑùÖÐSi£¬Ca£¬Mg£¬Al£¬FeÕ⼸ÖֳɷֵľßÌ庬Á¿ÊǶàÉÙ°¡£¿
ÒѾÓÐ1È˻ظ´

tianhui1998
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 554.8
- É¢½ð: 40
- ºì»¨: 2
- Ìû×Ó: 81
- ÔÚÏß: 31Сʱ
- ³æºÅ: 1279453
- ×¢²á: 2011-04-27
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
2Â¥2011-05-02 22:16:34
chendong0625
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 353.6
- É¢½ð: 50
- Ìû×Ó: 171
- ÔÚÏß: 35.6Сʱ
- ³æºÅ: 1092369
- ×¢²á: 2010-09-07
- רҵ: Ò©¼Áѧ

3Â¥2011-05-02 22:43:52
tianhui1998
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 554.8
- É¢½ð: 40
- ºì»¨: 2
- Ìû×Ó: 81
- ÔÚÏß: 31Сʱ
- ³æºÅ: 1279453
- ×¢²á: 2011-04-27
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
Sales Comment Consensus Sales Information Consensus forecast data for Roche are presented, and include sales for the related drug alteplase, with sales by Roche's subsidiary Genentech booked to Roche. No Consensus forecast data are available for Boehringer Ingelheim at this time. Reported Annual Sales Worldwide sales for tenecteplase (TNKase) and alteplase (Activase) reported by Roche for 2010 were CHF 460.0 million ($442.3 million), representing a year-on-year increase of 4% in local currency on 2009 [1183885]. Regional Development and Marketing Rights In January 2001, COR Therapeutics, Schering-Plough and Genentech announced a collaboration to copromote tenecteplase in hospitals across the US [395418]. In addition, F Hoffmann-La Roche secured exclusive licensing and marketing rights to tenecteplase in Canada. Actelion, as part of its tezosentan agreement with Genentech, was to also be involved in the copromotion of tenecteplase [401756]. Thomas pharm |
4Â¥2011-05-03 08:39:14
tianhui1998
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 554.8
- É¢½ð: 40
- ºì»¨: 2
- Ìû×Ó: 81
- ÔÚÏß: 31Сʱ
- ³æºÅ: 1279453
- ×¢²á: 2011-04-27
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï
warlen(½ð±Ò+1): ллӦÖú 2011-05-03 10:51:44
chendong0625(½ð±Ò+50): 2011-05-22 21:00:11
warlen(½ð±Ò+1): ллӦÖú 2011-05-03 10:51:44
chendong0625(½ð±Ò+50): 2011-05-22 21:00:11
|
ÏêϸµÄÎĵµ£ºhttp://www.rayfile.com/files/0c3 ... -874a-0015c55db73d/ Êý¾ÝÕª×Ô£ºRoche Finance Report 2010 |
5Â¥2011-05-03 08:45:11
chendong0625
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 353.6
- É¢½ð: 50
- Ìû×Ó: 171
- ÔÚÏß: 35.6Сʱ
- ³æºÅ: 1092369
- ×¢²á: 2010-09-07
- רҵ: Ò©¼Áѧ
ľЦЦ: ºÇºÇ 2011-05-22 22:11:34
|
ËäÈ»ÎÒÏÖÔڲſ´µ½ÄãµÄ»Ø¸´£¨ÂÛÎÄÔç½»ÉÏÈ¥ÁË£©£¬µ«ÊÇ»¹ÊÇÒª±íʾ¸Ðл¡£ ÖÔÐĵĸÐл¡£ |

6Â¥2011-05-22 21:06:45









»Ø¸´´ËÂ¥
20